Actively Recruiting
A Geospatial Analysis of Hotspots and Targeted Injection Settings Pilot Intervention for HIV Prevention Among People Who Inject Drugs in Baltimore, Maryland
Led by Johns Hopkins Bloomberg School of Public Health · Updated on 2026-05-22
285
Participants Needed
1
Research Sites
25 weeks
Total Duration
On this page
Sponsors
J
Johns Hopkins Bloomberg School of Public Health
Lead Sponsor
N
National Institute on Drug Abuse (NIDA)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are evaluating a pilot intervention aimed at reducing HIV and hepatitis C virus (HCV) transmission, as well as overdose risk behaviors, among people who inject drugs (PWID). The study uses a peer-driven approach targeting semi-public injection settings (SPIS) to promote safer practices. This intervention is grounded in social influence, social network, and social cognitive theories, focusing on improving communication and peer education to change social norms around risk behaviors. Participants will be randomly assigned to one of two groups: one receiving behavioral training with six sessions that include peer education and stocking of SPIS with risk reduction materials, and the other receiving an attention control (standard care). The intervention seeks to increase conversations about prevention and the availability of naloxone and other risk reduction materials in injection settings to reduce sharing of injection equipment and overdose risks. During the study, 120 index PWID participants will be selected based on their use of SPIS. Their involvement includes participation in the training sessions or control activities, with researchers monitoring overdose prevention and HIV/HCV prevention outcomes over six months. Assessments will include measures of overdose behaviors and related risk factors to evaluate how well the intervention influences these outcomes over time.
CONDITIONS
Brief Title
A Setting Focus Overdose Prevention Intervention
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Current drug user with opioid use in the prior two weeks
- Age 18 years or older
You will not qualify if you...
- Any mental or physical health impairment that impedes ability to participate in the study or training sessions
- Inability to provide informed consent or participate fully in study activities
- Any condition that would make participation unsafe or unfeasible as determined by investigators (if applicable based on health status assessment in screening process, though not explicitly stated in source, this is implied by impairment criteria but is not added as separate bullet here to adhere strictly to source text rules). Note: Only the explicit exclusion about mental or physical health impairment is included per source instructions; no additional criteria are invented.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 6 weeks
Participants receive behavioral training consisting of 6 sessions focused on HIV, HCV, and overdose prevention.
6 visits (in-person)
Duration - 6 months
Participants are monitored for overdose and HIV/HCV prevention outcomes after completing the behavioral training.
Periodic visits (visit schedule depends on study protocol)
Trial Site Locations
Total: 1 location
1
Lighthouse Studies at Peer Point
Baltimore, Maryland, United States, 21205
Actively Recruiting
Research Team
C
Carl Latkin, PhD
L
Lauren Dayton, PhD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
HEALTH_SERVICES_RESEARCH
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here